

9

REMARKS

By this amendment claims 25-26 are cancelled, claim 27 is amended and claims 36-43 are new. Claims 1-24 were previously cancelled and claims 28-34 were previously withdrawn.

Claim 27 has been amended by specifying that the method relates to the treatment of allergy and asthma patients in need of such treatment, based for example on the original claim 5. Claim 27 formerly referred to claim 25 and this has now been replaced by a positive recitation that the treatment comprises administering a pharmaceutical composition consisting essentially of glycoposphopeptical. Claim 27 has also been clarified by stating that the administration takes place in multiple doses for a short term treatment period of 1-20 days. Basis for multiple doses comes for example from page 8 lines 14-15. The 1-20 day treatment period is disclosed on original page 10, lines 7-10. The period of remission produced by the treatment has been specified as "several months", based for example on page 7, line 21 ("a long-term clinical remission of months..."). For clarity, it has been specified that further treatment is not necessary during the remission period, which is inherent from the direct meaning of remission since clearly the remission of the ailment means that the patient is not in need of further treatment.

New claim 35 specifies that the short term treatment period lasts 3-5 days, based for example on page 8, line 14.

New claim 36 specifies that the glycoposphopeptical is administered in doses up to 2000mg, for example based on page 8 line 16 and new claim 37 specifies 200-1000mg, based for example also on page 8, line 16.

New claim 38 specifies that the glycoposphopeptical is administered in doses at least once daily up to 10 times daily: see page 8, line 15.

New claim 39 specifies that the glycoposphopeptical is administered orally as capsules, tablets, lozenges, a powder or a syrup, as disclosed at page 8 lines 17-18.